Sonnet BioTherapeutics Holdings, Inc. reported earnings results for the first quarter ended December 31, 2023. For the first quarter, the company reported net loss was USD 1.17 million compared to USD 5.54 million a year ago. Basic loss per share from continuing operations was USD 0.31 compared to USD 17.62 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.77 USD | +0.57% | -2.75% | +1.72% |
Mar. 11 | Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street | MT |
Mar. 11 | Top Premarket Gainers | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+1.72% | 5.43M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- SONN Stock
- News Sonnet BioTherapeutics Holdings, Inc.
- Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023